-
News Center
Boehringer's new drug Spiriva Respimat is approved to replace the No
2023-10-27
Boehringer Ingelheim,a specialist in respiratory diseases,developed Spiriva Respimat,a new drug for COPD that was rejected by the FDA in 2007.Subsequently,a large global COPD clinical study was conducted,demonstrating efficacy and safety.Recently,the FDA finally approved Spiriva Respimat,which shares the same composition as Spiriva HandiHaler,the most prescribed drug in the COPD market,but its aerosol formulation offers comfort and convenience advantages that will especially benefit newly diagnosed COPD patients.The industry predicts that Spiriva Respimat will replace Spiriva HandiHaler as the leader in the COPD market and achieve blockbuster sales.
2023-10-27
In November 2013,Professor Qi Yue and Professor Zhao Dong of Beijing Anzhen Hospital Affiliated to Capital Medical University conducted a study to explore whether the synthesis/absorption status of cholesterol affects the cholesterol-lowering effect of statins and whether it can predict the cholesterol-lowering effect of statins.
A breakthrough in stem cell research could lead to a cure for diabetes
2023-10-27
Douglas Melton,a developmental biologist at the Harvard Stem Cell Institute,and colleagues report in the journal Cell that a new technique can successfully transform human embryonic stem cells(ESCs)or induced pluripotent stem cells(IPscs)into functional pancreatic beta cells.These beta cells secrete insulin to regulate glucose levels,just like normal beta cells.And experiments in mice have shown that these cells can cure type 1 diabetes.
2023-10-27
Recently,the development of lipid-lowering drugs is very hot.On Oct.1,a new lipid-lowering drug from Esperion Therapeutics,ETC-1002,not only outperformed Merck's Zetia(generic name:Ezetimibe)in a mid-stage clinical trial,but more importantly,a combination of the two performed better.On October 2,The Lancet reported two key clinical results for Amgen's PCSK9 inhibitor Evolocumab(Rutherford-2 and Tesla PartB).In a randomized,double-blind,placebo-controlled international multi-center clinical trial(Rutherford-2),Evolocumab in combination with a statin-lowering drug or Zetia reduced LDL levels by 60% in patients with familial heterozygous hypercholesterolemia(FH).In such patients,high doses of statins combined with Zetia often fail to bring LDL levels down to recommended levels.
Boehringer's new drug Spiriva Respimat is approved to replace the No
Boehringer Ingelheim,a specialist in respiratory diseases,developed Spiriva Respimat,a new drug for COPD that was rejected by the FDA in 2007.Subsequently,a large global COPD clinical study was conducted,demonstrating efficacy and safety.Recently,the FDA finally approved Spiriva Respimat,which shares the same composition as Spiriva HandiHaler,the most prescribed drug in the COPD market,but its aerosol formulation offers comfort and convenience advantages that will especially benefit newly diagnosed COPD patients.The industry predicts that Spiriva Respimat will replace Spiriva HandiHaler as the leader in the COPD market and achieve blockbuster sales.
2016-12-14
In November 2013,Professor Qi Yue and Professor Zhao Dong of Beijing Anzhen Hospital Affiliated to Capital Medical University conducted a study to explore whether the synthesis/absorption status of cholesterol affects the cholesterol-lowering effect of statins and whether it can predict the cholesterol-lowering effect of statins.
2016-12-14
A breakthrough in stem cell research could lead to a cure for diabetes
Douglas Melton,a developmental biologist at the Harvard Stem Cell Institute,and colleagues report in the journal Cell that a new technique can successfully transform human embryonic stem cells(ESCs)or induced pluripotent stem cells(IPscs)into functional pancreatic beta cells.These beta cells secrete insulin to regulate glucose levels,just like normal beta cells.And experiments in mice have shown that these cells can cure type 1 diabetes.
2016-12-14
Recently,the development of lipid-lowering drugs is very hot.On Oct.1,a new lipid-lowering drug from Esperion Therapeutics,ETC-1002,not only outperformed Merck's Zetia(generic name:Ezetimibe)in a mid-stage clinical trial,but more importantly,a combination of the two performed better.On October 2,The Lancet reported two key clinical results for Amgen's PCSK9 inhibitor Evolocumab(Rutherford-2 and Tesla PartB).In a randomized,double-blind,placebo-controlled international multi-center clinical trial(Rutherford-2),Evolocumab in combination with a statin-lowering drug or Zetia reduced LDL levels by 60% in patients with familial heterozygous hypercholesterolemia(FH).In such patients,high doses of statins combined with Zetia often fail to bring LDL levels down to recommended levels.
2016-12-14
TEL.
E-MAIL.
ADD.
No.28, Chuangye Avenue, Gedian Development Zone, Ezhou City, Hubei Province, China
WeChat Public
SAF Coolest v1.3 设置面板 EIMSX-ZHWH-HQAWE-ZAD
无数据提示
Sorry，当前栏目暂无内容！
您可以查看其他栏目或返回 首页